CSIMarket
 
Gritstone Bio Inc   (GRTS)
Other Ticker:  
 
 
Price: $2.0200 $-0.78 -27.857%
Day's High: $2.27 Week Perf: -17.55 %
Day's Low: $ 1.85 30 Day Perf: -15.48 %
Volume (M): 6,339 52 Wk High: $ 3.33
Volume (M$): $ 12,804 52 Wk Avg: $2.09
Open: $2.10 52 Wk Low: $1.14



 Market Capitalization (Millions $) 233
 Shares Outstanding (Millions) 115
 Employees -
 Revenues (TTM) (Millions $) 10
 Net Income (TTM) (Millions $) -71
 Cash Flow (TTM) (Millions $) -29
 Capital Exp. (TTM) (Millions $) 4

Gritstone Bio Inc
Gritstone Bio Inc is a biotechnology company that focuses on developing personalized cancer immunotherapies. They utilize a unique approach called argeted epitope discovery to identify and validate tumor-specific antigens, which are then used to create personalized immunotherapies that specifically target and destroy cancer cells. Gritstone Bio aims to improve the outcomes of cancer patients by developing innovative and effective immunotherapies.


   Company Address: 5959 Horton Street Emeryville 94608 CA
   Company Phone Number: 871-6100   Stock Exchange / Ticker: NASDAQ GRTS
   GRTS is expected to report next financial results on March 08, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Gritstone Bio Announces Delay in Phase 2b COVID-19 Clinical Trial for Optimal Vaccine Development

Published Mon, Feb 12 2024 12:00 PM UTC

EMERYVILLE, Calif., Feb. 12, 2024 - Gritstone bio, Inc. (Nasdaq: GRTS), a pioneering biotechnology company focused on developing the world's most powerful vaccines, has shared an important update on its comparative Phase 2b COVID-19 clinical trial. The company is now preparing to launch the much-anticipated trial in the Fall of 2024, rather than the previously scheduled 1Q24...

Shares

Gritstone Bio's Stock Option Grants to New Employees Raise Concerns for Shareholders

Published Thu, Feb 8 2024 9:30 PM UTC

Pharmaceutical Company Gritstone Bio Grants Stock Options to New Employees, Impacting Shareholders
Emeryville, California - Gritstone Bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company renowned for developing the world's most potent vaccines, recently announced the granting of nonqualified stock options to six employees. The options allow them to purchase a...

Gritstone Bio Inc

Gritstone Bio Inc Faces Crumbling Revenues with a Shocking -48% Decline, Leaving Investors Worried

As an avid observer of the financial markets, I couldn't help but notice the disappointing fiscal results recently announced by Gritstone Bio Inc. The biotechnology and pharmaceuticals company reported a significant decline in revenue, which melted down by a staggering -48.196% to $1.57 million for the fiscal interval ending September 30, 2023. This is in stark contrast to the previous year's similar span, where revenue stood at $1.96 million, reflecting a decline of -19.949%.
Moreover, Gritstone Bio Inc recorded a shortfall per share amounting to $-0.33, a slight improvement from $-0.35 in the preceding reporting period. It is worth noting that this is an improvement from the increased loss of $-0.31 per share reported in the same period last year.

Gritstone Bio Inc

Gritstone Bio Inc Faces Grim Reality: Q2 2023 Puts Company in Financial Freefall, Revenue Plunges by 64.266%

Financial Report: Gritstone Bio Inc Shows Losses in Q2 2023, Revenue Plummets
Gritstone Bio Inc, a biotechnology company focusing on cancer immunotherapy, experienced a net loss of $-35.256 million for the financial interval closing June 30, 2023. This loss is larger than the $-29.515 million reported in the same period a year ago. The company's financial performance has been underwhelming, showing a loss of $-0.31 per share compared to $-0.34 per share a year prior. Furthermore, Gritstone Bio Inc's loss grew from $-0.30 per share in the preceding reporting period.
In terms of revenue, Gritstone Bio Inc witnessed a sharp decline of -64.266% to $1.96 million from $5.47 million in the same reporting period a year prior. Sequentially, the revenue fell by -19.975% from $2.44 million. These numbers indicate a notable decrease in the company's revenue streams.

Gritstone Bio Inc

1. Gritstone Bio Inc.'s Remarkable Turnaround: First Quarter of 2023 Sees Massive Revenue Boost2. Subtitle: Efficient Resource Management and Profit Maximization Propel Gritstone Bio to New Heights

Gritstone Bio Inc. is a leading player in the biotechnology industry that has recently reported its financial earnings for the first quarter of 2023. While the company incurred losses of $-0.30 per share in the current earnings season, it has witnessed a significant improvement over the previous year's losses of $-0.34 per share. Moreover, compared to the previous reporting season, Gritstone Bio Inc. has also managed to cut its losses from $-0.28 per share to $-0.30 per share. This performance has given hope to investors, who see the company's potential to turn things around in the future.
One of the most significant factors contributing to Gritstone Bio's improved performance in the first quarter of 2023 was its net earnings, which stood at $33.982 million. This is a notable improvement compared to a net loss of $-28.916 million incurred in the corresponding reporting season a year ago. This performance highlights the company's focus on managing its resources efficiently and maximizing its profits.






 

Gritstone Bio Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com